(AFX UK Focus) 2009-12-21 06:15 Pfizer to buy stem-cell therapy from Athersys
Dec 21 (Reuters) – Pfizer Inc, the world’s biggest drugmaker, is buying the rights to a stem-cell therapy to treat inflammatory bowel disease from Athersys Inc, the New York Times said on its website late on Sunday. Pfizer will pay Athersys $6 million initially and up to $105 million in the future, according to the paper. Athersys’s cells, which are derived from human bone marrow, have yet to be …
[Read the full article here]Related News:
Pfizer Acquires a Stem-Cell Therapy
Athersys Soars On Stem Cell Development Deal with Pfizer
Athersys still excited about Pfizer stem cell collaboration